Deciphera Pharmaceuticals, Inc.

NasdaqGS:DCPH Stock Report

Market Cap: US$1.2b

Deciphera Pharmaceuticals Dividend

Dividend criteria checks 0/6

Deciphera Pharmaceuticals does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield2.7%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per share-US$2.41
Dividend yield forecast in 3Yn/a

Recent dividend updates

No updates

Recent updates

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Mar 13
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Dec 02
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?

Sep 25
Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Jul 26
Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Jun 22
Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S

May 08
Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Apr 10
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Dec 29
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside

Aug 29

Deciphera Pharmaceuticals Q2 2022 Earnings Preview

Aug 03

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully

Jul 29
We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully

Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now

Feb 11

Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified

Nov 22

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Aug 26
Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Deciphera Pharmaceuticals posts data from cancer studies at ASCO21

Jun 04

Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth

May 10
Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth

Growth Investors: Industry Analysts Just Upgraded Their Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Revenue Forecasts By 16%

Feb 11
Growth Investors: Industry Analysts Just Upgraded Their Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Revenue Forecasts By 16%

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Feb 05
Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Deciphera to expand geographic reach and clinical potential of ripretinib

Jan 11

Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Intrinsic Value Is Potentially 72% Above Its Share Price

Dec 15
Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Intrinsic Value Is Potentially 72% Above Its Share Price

Deciphera completes enrollment in late-stage study of ripretinib in GIST patients

Nov 30

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if DCPH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DCPH's dividend payments have been increasing.


Dividend Yield vs Market

Deciphera Pharmaceuticals Dividend Yield vs Market
How does DCPH dividend yield compare to the market?
SegmentDividend Yield
Company (DCPH)n/a
Market Bottom 25% (US)1.5%
Market Top 25% (US)4.7%
Industry Average (Biotechs)2.7%
Analyst forecast in 3 Years (DCPH)n/a

Notable Dividend: Unable to evaluate DCPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DCPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate DCPH's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as DCPH has not reported any payouts.


Discover strong dividend paying companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.